A Phase III Trial of ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transplantation (UCBT) in Patients With Inborn Errors of Metabolism

Trial Profile

A Phase III Trial of ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transplantation (UCBT) in Patients With Inborn Errors of Metabolism

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2014

At a glance

  • Drugs ALD 101 (Primary)
  • Indications Adrenoleucodystrophy; Alpha-Mannosidosis; Canavan disease; Gangliosidoses; Globoid cell leukodystrophy; Metachromatic leukodystrophy; Mucolipidoses; Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis III; Mucopolysaccharidosis VI; Niemann-Pick diseases; Pelizaeus-Merzbacher disease; Tay-Sachs disease
  • Focus Therapeutic Use
  • Sponsors Aldagen
  • Most Recent Events

    • 07 Jul 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 12 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top